NX-210c is under clinical development by Axoltis Pharma and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NX-210c’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NX-210c overview

NX-210c is under development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease. The drug candidate is NX-210 analog which is a synthetic peptide derived from subcommissural organ-spondin. It is administered through intravenous route.

It was also under development for spinal cord injury.

Axoltis Pharma overview

Axoltis Pharma is a biopharmaceutical company that develop therapies for patients with traumatic and severe neurological disorders. The company offers NX210, a candidate-drug to promote regeneration of nerve fibers to support functional improvement and used to treat additional indications such as alzheimer’s and parkinson’s diseases, myelin disorders and other non-CNS applications. It also offers NX210 and analogs; and regenerative medicine. The company offers services such as customized services, cell culture, in vitro evaluation, neurotrophic and neuroprotective effects, culture analyses and stem cells. It operates offices in Saint Beauzire and Lyon, France. Axoltis Pharma is headquartered in Clermont-Ferrand, France.

For a complete picture of NX-210c’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.